<DOC>
	<DOCNO>NCT01708005</DOCNO>
	<brief_summary>The purpose study compare effect 12 week oral intake Lecitone®Se + 200UI/day D3 vitamin effect placebo change cognitive performance Trial Making Test score part B ( test evaluate executive function mental flexibility ) old adult Mild Cognitive Impairment ( MCI ) .</brief_summary>
	<brief_title>DIetary Supplements , Executive funcTions Vitamin D ( DIET-D )</brief_title>
	<detailed_description>Current treatment Alzheimer 's disease ( AD ) symptomatic temporarily slow AD without alter natural evolution . The development new therapy primarily focus prevent progression AD . This therapeutic strategy involve interested patient early stage AD mild cognitive impairment ( MCI ) . We hypothesize combination Lecitone®Se 200 IU/day vitamin D slow even improve cognitive decline , particularly executive function . The primary objective trial compare effect 12 week oral intake Lecitone®Se-Vitamin D3 effect placebo change performance obtain TMT B old adult MCI . The secondary objective study follow : - To compare effect 12 week oral intake Lecitone®Se-Vitamin D3 effect placebo change executive performance patient MCI . - To compare effect 12 week oral intake Lecitone®Se-Vitamin D3 effect placebo change variability stride time patient MCI . - To compare effect 24 week oral intake Lecitone®Se-Vitamin D3 effect placebo delay phase supplementation change executive performance patient MCI . - To compare effect 24 week oral intake Lecitone®Se-Vitamin D3 effect placebo delay phase supplementation change variability stride time patient MCI . - To determine compliance tolerance oral intake Lecitone®Se-Vitamin D3 patient MCI .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Age ≥ 60 year Memory complaints No dementia ( DSMIV , NINCDSADRDA negative ) No depression ( Geriatric Depression score ≤ 5/15 ) Ability walk distance 15 meter unaided Diagnosis MCI To hypovitaminosis D ( i.e . serum 25hydroxyvitamin D [ 25OHD ] concentration ≤ 30ng/mL ) To hypercalcemia ( define serum calcium concentration ≥ 2,65mmol/L ) To give sign informed consent participate trial To affiliate French Social Security Others cognitive disorder ( untreated thyroid dysfunction , chronic ongoing ethylism , history syphilis , stroke , severe depressive symptomatology ( Geriatric Depression score &gt; 5/15 ) , existence dementia accord DSMIV NINCDSADRDA criterion time inclusion ) Vitamin D supplementation inclusion Contraindications vitamin D Unstable medical condition Enrollment another simultaneous clinical trial Civil defense measure underway</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Cholecalciferol</keyword>
	<keyword>Lecitone®Se-Vitamin D3</keyword>
</DOC>